• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Healthcare

Profit From the Fed's Words

When the Fed knocks down certain market sectors, we value investors know what to do.
By SHAM GAD Jul 23, 2014 | 01:00 PM EDT
Stocks quotes in this article: KIN, OESX

A couple of weeks ago, when the minutes of the last Federal Open Market Committee meeting were released, investors were treated to the Fed rhetoric we are all accustomed to. Yet investors got another surprise. The Fed, perhaps for the first time in history, actually offered investment advice. Fed Chair Janet Yellen commented that small-cap and biotech stocks had gotten overvalued. 

So guess what happened. Small-caps and biotechs sold off. So guess what you should consider doing as an investor. Look for ideas as a result of the selloff. My own very humble opinion is that the Fed is designed to manage monetary policy and not necessarily speculate on the state of investments. I'm not suggesting the assessment was wrong -- small-caps and biotechs have been red-hot areas. But because the Fed has the unique power of truly moving markets with every word it releases, it must choose those words carefully.

As a result of those comments, names such as Kindred Biosciences (KIN), a biotech that specializes in therapies for animals, sold off a bit and now sits at $15.30. I've written a few times about why this biotech is a different animal from the rest (no pun intended). Kindred is exclusively focused on pet drugs, which cost less to fund through the development process, have a shorter trial period and have a lower FDA hurdle than drugs for humans. Kindred has a healthy pipeline and expects to have products out to market next year. The stock went public at $8.75, raced to $27 and has fallen back, valuing the company at $300 million. With a couple of drug approvals, Kindred could be a billion-dollar company in a few years.

Orion Energy Systems (OESX) is a specialty lighting company trading at $4.33, for a market cap of $94 million. The balance sheet is clean with over $10 million in net cash. Orion focuses on light-emitting diodes, an efficient lighting technology that has the potential to grow in the coming years. The lighting market is experiencing a transition. A new management team was brought in 2012, and it has focused on cost-cutting and sales growth.

Orion's state-of-the-art facility is currently operating at 20% capacity. That means the company will incur very low fixed investment costs to expand production when demand grows. LEDs have historically been expensive, despite their long life and superior lighting quality. But that perception is changing as production costs decline and more segments gravitate to the benefits of LED lighting. LED growth catalysts include improving costs, superior light quality and reduced maintenance cost by the end user.

If the Fed wants to lower equity prices for investors, I welcome that development with open arms. Price is what determines future return, and the lower the entry point, the better.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Gad was long KIN.

TAGS: Investing | U.S. Equity | Healthcare | Technology

More from Healthcare

Johnson & Johnson Appears to Be Running Out of Steam

Bruce Kamich
Jun 22, 2022 8:25 AM EDT

The shares of the healthcare giant have been in a long-term uptrend but could break that trend in the weeks ahead.

Anthem's Long-Term Uptrend Is Losing Its Vigor

Bruce Kamich
Jun 22, 2022 7:40 AM EDT

The technical signals of the health benefits provider are weakening.

Here Are 2 Prudent Healthcare Trades

Bret Jensen
Jun 17, 2022 11:30 AM EDT

The country might be heading into recession, but folks still need to get their medicine, good times or bad.

Here's the Level to Zero In on for UnitedHealth Group

Bruce Kamich
Jun 13, 2022 7:29 AM EDT

Shares of the diversified healthcare company have held up fairly well despite the decline in the broader market but soon could be put to the test.

3 Dividend-Paying Healthcare Stocks That Age Well

Bob Ciura
Jun 5, 2022 12:30 PM EDT

Within the next 15 years, people 65 or older are expected outnumber those under 18, for the first time in U.S. history.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 12:04 AM EDT PAUL PRICE

    Two Good Signs -- Especially for Small-Cap Investors

  • 12:10 AM EDT PAUL PRICE

    More Insider Buying in American Woodmark (AMWD)

    American Woodmark , which I've discussed here fr...
  • 08:55 AM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    The 10 personality traits of successful traders an...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2022 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login